Facing acute neuromuscular diseases during COVID-19 pandemic: focus on Guillain-Barré syndrome.
Acta Neurol Belg
; 120(5): 1067-1075, 2020 Oct.
Article
in English
| MEDLINE | ID: covidwho-663658
ABSTRACT
In December 2019, a cluster of cases with 2019 Novel Coronavirus pneumonia from Wuhan, China, aroused worldwide concern due to an escalating outbreak in all the countries in the world. Coronavirus belongs to a family of single-stranded RNA viruses, which includes severe acute respiratory syndrome (SARS-CoV) and Middle East respiratory syndrome (MERS-CoV), that have caused human epidemics with high fatality. The spectrum of the novel coronavirus disease (SARS-Co-2 or COVID-19) ranges from asymptomatic infections to fatal pneumonia, and differs from other viral pulmonary infections. MERS-CoV is known to be potentially neuroinvasive. Extensive reports from China documented central and peripheral nervous system involvement in patients with COVID-19, and identified in angiotensin converting enzyme2 (ACE2), which is present in multiple human organs, the functional receptor for this virus. Guillain-Barré syndrome (GBS) has recently been associated to COVID-19 rising concern among physicians. This review summarizes the current state of knowledge on GBS during or after COVID-19 infection, attempting to clarify the pathophysiology of the associated respiratory dysfunction and failure.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Pneumonia, Viral
/
Coronavirus Infections
/
Guillain-Barre Syndrome
Topics:
Long Covid
Limits:
Humans
Language:
English
Journal:
Acta Neurol Belg
Year:
2020
Document Type:
Article
Affiliation country:
S13760-020-01421-3
Similar
MEDLINE
...
LILACS
LIS